AC
STOK icon

Amitell Capital’s Stoke Therapeutics STOK Stock Holding History

Amitell Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-64,807
Closed -$856K – 29
2022
Q2 		$856K Hold
64,807
– – 1.95% 13
2022
Q1 		$1.36M Buy
+64,807
New +$1.3M 0.79% 45

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Amitell Capital's STOK Position: Q3 2022 in Review

Amitell Capital sold out of Stoke Therapeutics (STOK) in Q3 2022, closing a stake of 64,807 shares — an estimated $856K sold.

Amitell Capital first reported a position in STOK in Q1 2022 and held it in 2 quarters. The position peaked at $1.36M in Q1 2022. 105 funds tracked by Wall St. Rank hold STOK as of Q3 2022.

  • Amitell Capital reported no remaining Stoke Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Amitell Capital sold 64,807 Stoke Therapeutics shares in Q3 2022, an estimated $856K.
  • Amitell Capital first reported a position in Stoke Therapeutics in Q1 2022 and held it in 2 quarters.
  • Amitell Capital's Stoke Therapeutics position peaked at $1.36M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2022.

Based on Amitell Capital's 13F filing for Q3 2022, filed 10 Nov 2022.